Alcobra Applies Revisionist History to ADHD Drug Study Analysis

TEL AVIV, Israel (TheStreet) — Alcobra disclosed in a regulatory filing Wednesday night new details about the phase III study ofaattention-deficit hyperactivity disorder drug candidate MDX which contradict results announced by theacompany in an Oct. 6 press release. The newly disclosed differences and omissions are serious enough to raise questions about whetheraAlcobra executives mis …

from Content Keyword RSS


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s